drugset / Trial / NCT00101166
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
Phase 2
Completed
43 enrolled
H. Lee Moffitt Cancer Center and Research Institute
American Society of Clinical Oncology · collabNational Cancer Institute (NCI) · collabSociety of Surgical Oncology (SSO) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects (good and/or bad) this new cancer vaccine has on the patient and their cancer, whether it is safe and whether it can help get rid of their cancer (malignant melanoma). We want to check how the patient's immune system reacts, both before and after the vaccine treatment.
Timeline
- Start
- 2004-10
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bystander-Based Autologous Tumor Cell Vaccine | Vaccine | 1 ml | Intrathecal |